A recent study, published in the Journal of Cancer Research and Clinical Oncology this month, has investigated the effect of taking concomitant medication for renal cell carcinoma (RCC) in 388 patients who had surgery for localised kidney cancer. They also looked at various biomarkers for these concomitant medications.

The researchers discovered that concomitant use of statins and sartans improved overall survival in patients with localised RCC, and were independent predictors of survival. They also discovered that reduced levels of Ki67, a biomarker for cancer cell growth, was significantly associated with statin use. The researchers recommend further investigations into these effects.

Read more in UroToday here